Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Global congenital hyperinsulinism treatment industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug type trends
2.1.4 Route of administration trends
2.1.5 Ditribution channel trends
Chapter 3 Congenital Hyperinsulinism Treatment Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of congenital hyperinsulinism (CHI)
3.2.1.2 Increasing focus on personalized medicine
3.2.1.3 Favorable government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited approved treatment options
3.2.2.2 High treatment cost
3.3 Growth potential analysis
3.3.1 By drug type
3.3.2 By route of administration
3.3.3 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Company positioning matrix
4.5 Strategy dashboard, 2022
Chapter 5 Congenital Hyperinsulinism Treatment Market Size and Forecast, By Drug Type (USD Million)
5.1 Key trends, by drug type
5.2 Diazoxide
5.3 Octreotide
5.4 Nifedipine
5.5 Glucagon
5.6 Other drug types
Chapter 6 Congenital Hyperinsulinism Treatment Market Size and Forecast, By Route of Administration (USD Million)
6.1 Key trends, by route of administration
6.2 Oral
6.3 Parenteral
Chapter 7 Congenital Hyperinsulinism Treatment Market Size and Forecast, By Distribution Channel (USD Million)
7.1 Key trends, by distribution channel
7.2 Retail pharmacies
7.3 Hospital pharmacies
7.4 Online pharmacies
Chapter 8 Congenital Hyperinsulinism Treatment Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Crinetics Pharmaceuticals, Inc.
9.2 Novartis AG
9.3 Zealand Pharma A/S
9.4 Rezolute, Inc.
9.5 Hanmi Pharm.Co.,Ltd
9.6 Teva Pharmaceutical Industries Ltd
9.7 Eli Lilly and Company
9.8 Eiger BioPharmaceuticals
9.9 AmideBio, LLC
9.10 Xeris Pharmaceuticals, Inc.
